<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Fortin JS</submitter><funding>NIA NIH HHS</funding><funding>Purdue University</funding><funding>NINDS NIH HHS</funding><funding>National Institutes of Health</funding><funding>Pharmaceutical Research and Manufacturers of America Foundation</funding><pagination>133574</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9614895</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>1267</volume><pubmed_abstract>In contrast to A&lt;i>β&lt;/i> plaques, the spatiotemporal distribution of neurofibrillary tangles of hyperphosphorylated tau (p-tau) predicts cognitive impairment in Alzheimer's disease (AD), underscoring the key pathological role of p-tau and the utmost need to develop AD therapeutics centering upon the control of p-tau aggregation and cytotoxicity. Our drug discovery program is focused on compounds that prevent the aggregation and cytotoxicity of p-tau moieties of the tau isoform 1N4R due to its prevalence (1 N) and long-distance trans-synaptic propagation (4R). We prepared and tested twenty-four newly synthesized small molecules representing the urea (&lt;b>1, 2, 3&lt;/b>), sulfonylurea (&lt;b>4&lt;/b>), and sulfonamide (&lt;b>5-24&lt;/b>) series and evaluated their anti-aggregation effects with biophysical m</pubmed_abstract><journal>Journal of molecular structure</journal><pubmed_title>Anti-fibrillization effects of sulfonamide derivatives on &lt;i>α&lt;/i>-synuclein and hyperphosphorylated tau isoform 1N4R.</pubmed_title><pmcid>PMC9614895</pmcid><funding_grant_id>R21AG070447-01A1</funding_grant_id><funding_grant_id>R21 NS121826</funding_grant_id><funding_grant_id>K08 AG071985</funding_grant_id><funding_grant_id>P01 AG014449</funding_grant_id><funding_grant_id>NS121826</funding_grant_id><funding_grant_id>NS099328</funding_grant_id><funding_grant_id>P01AG014449</funding_grant_id><funding_grant_id>R01 NS099328</funding_grant_id><funding_grant_id>R21 AG070447</funding_grant_id><funding_grant_id>R44 AG057274</funding_grant_id><funding_grant_id>R01 AG062435</funding_grant_id><funding_grant_id>R01 AG060731</funding_grant_id><funding_grant_id>R01AG060731</funding_grant_id><funding_grant_id>R01AG062435</funding_grant_id><funding_grant_id>730313</funding_grant_id><funding_grant_id>R44AG57274</funding_grant_id><pubmed_authors>Borhan B</pubmed_authors><pubmed_authors>Liu M</pubmed_authors><pubmed_authors>Wang KW</pubmed_authors><pubmed_authors>Maity S</pubmed_authors><pubmed_authors>Kuo MH</pubmed_authors><pubmed_authors>Fortin JS</pubmed_authors><pubmed_authors>Saraswati AP</pubmed_authors><pubmed_authors>Hagar HT</pubmed_authors><pubmed_authors>Shimanaka K</pubmed_authors><pubmed_authors>Dettmer U</pubmed_authors><pubmed_authors>Ellsworth E</pubmed_authors><pubmed_authors>Ganegamage SK</pubmed_authors><pubmed_authors>Counts SE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Anti-fibrillization effects of sulfonamide derivatives on &lt;i>α&lt;/i>-synuclein and hyperphosphorylated tau isoform 1N4R.</name><description>In contrast to A&lt;i>β&lt;/i> plaques, the spatiotemporal distribution of neurofibrillary tangles of hyperphosphorylated tau (p-tau) predicts cognitive impairment in Alzheimer's disease (AD), underscoring the key pathological role of p-tau and the utmost need to develop AD therapeutics centering upon the control of p-tau aggregation and cytotoxicity. Our drug discovery program is focused on compounds that prevent the aggregation and cytotoxicity of p-tau moieties of the tau isoform 1N4R due to its prevalence (1 N) and long-distance trans-synaptic propagation (4R). We prepared and tested twenty-four newly synthesized small molecules representing the urea (&lt;b>1, 2, 3&lt;/b>), sulfonylurea (&lt;b>4&lt;/b>), and sulfonamide (&lt;b>5-24&lt;/b>) series and evaluated their anti-aggregation effects with biophysical m</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2026-05-27T12:06:29.566Z</modification><creation>2024-11-08T20:15:57.446Z</creation></dates><accession>S-EPMC9614895</accession><cross_references><pubmed>36310922</pubmed><doi>10.1016/j.molstruc.2022.133574</doi></cross_references></HashMap>